ADIA & BDIA Forge Ties To Support The Industry
19th Mar 18
Collaboration on efforts to support dental product manufacturers and suppliers in Australia and Britain is the key outcome of a new agreement between ADIA and BDIA to be signed this week in Sydney.
Key Issues For The Dental Industry —
Two of the leading organisations representing dental product manufacturers and suppliers will sign a cooperative agreement that strengthens an informal working relationship that's existed over more than fifty years,
The Australian Dental Industry Association (ADIA) and the British Dental Industry Association (BDIA) have negotiated an agreement that establishes a new framework for information sharing and cooperation on issues of mutual interest.
The dental industry in Australia and Britain jointly understand the importance of the role that industry has in supporting dental professionals to deliver optimal oral health. This is achieved through the investment by dental product manufacturers in new and innovative patient treatment options and in this area there is so much that the ADIA and BDIA membership can learn from each other.
ADIA and BDIA share the policy objective of achieving convergence of the regulations for the market approval of medical devices. Given that in Australia and in Britain the regulatory framework for the approval of medical devices is based upon that of the European Union there, the membership of both organisations will benefit as a result of a broad understanding and differing perspectives on matters associated with product regulation.
In the context of Brexit it’s likely that, in many respects, Britain’s dental product regulatory framework may eventually look increasingly like that of Australia. We expect that in the coming years, just like in Australia, the regulations will be based heavily upon those of Europe but with some opportunities for important changes that reflect local conditions.
Another important area where the membership of ADIA and BDIA stand to benefit from the agreement is in the area of promoting their respective members’ products overseas. Both organisations will be hosting national pavilions at key international dental trade shows such as IDS Cologne and IDEM Singapore.
The agreement between ADIA and BDIA will be signed at ADX18 Sydney, Australia’s premier dental event and the nation’s largest healthcare tradeshow that’s being held over 23-25 March 2018 at the International Convention Centre Sydney.
Member engagement —
ADIA provides leadership, strategy, advocacy and support. Our members set our agenda, fund our activities and directly benefit from the results. With respect to the BDIA agreement it was approved by the ADIA Board in the context of the ADIA Stakeholder Engagement Strategy to progress projects and policies developed by members serving on ADIA National Committees.
Currency & Disclaimer —
This update was issued on 19 February 2018 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This publication is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, other images and where otherwise stated.
|A —.. A D I A . .S T R A T E G I C . .A L L I A N C E S
21st May 18
The next edition of the Australian Dental Industry Intelligence Report is currently being prepared, a document that assesses the value of the market for dental products and its growth over the past decade.
17th May 18
The Australian Government has launched a national awareness campaign to get to get more Australians into ground-breaking clinical trials with the objective of offering better diagnosis, treatment and ultimately care.